« Back
Immatics presenting at SITC Annual Meeting 2021
Nov 10 - Nov 14, 2021
Join Immatics at the Society for Immunotherapy of Cancer (SITC) Annual Meeting & Pre-Conference Programs, which brings together stakeholders across the cancer immunotherapy field to advance the science, discover breakthroughs and educate the world on cancer immunotherapy.
Saturday, November 13, 12:00 - 12:15pm EDT
IMA203 Phase 1a Clinical Data Update:
Presentation Title: Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses – clinical update on the ACTengine® IMA203 trial
Speaker: Martin Wermke, MD, Coordinating Investigator of Immatics ACTengine® trials in Germany and Head of the Early Clinical Trial Unit of the National Center for Tumor Diseases Dresden (NCT/UCC) at the University Hospital Carl Gustav Carus in Dresden, Germany
Abstract Number: 959
Category: Late-breaking oral abstract presentation
Friday, November 12, 7 am–8:30 pm EDT
Next-generation CD8ab TCR-T approach - Preclinical Data Update:
Presentation Title: Improved anti-tumor activity of next-generation TCR-engineered T cells through CD8 co-expression
Speaker: Mamta Kalra, PhD, Director CMC (Process Development) at Immatics
Abstract Number: 163
Category: Poster abstract presentation
All posters presented at the poster hall will be made available as virtual ePosters throughout the SITC 36th Annual Meeting.
For more information please visit the event's website: SITC Annual Meeting 2021
Supporting Materials
Location